A Study For Pregabalin In Patients With Fibromyalgia
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Jun 30, 2011
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female patients, at least 18 years of age
- • Meeting the ACR (America College of Rheumatology) criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)
- • At screening (V1) and randomization (V2), patients must have a score of no less than 40 mm on the Pain Visual Analog Scale (VAS)
- • At randomization (V2), at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be no less than 4
- Exclusion Criteria:
- • Patients with no less than 30% decrease on the Pain Visual Analog Scale (VAS) at randomization (V2) as compared to screening (V1)
- • Patients with other severe pain due to other conditions (eg, DPN or PHN) that may confound assessment or self-evaluation of the pain associated with fibromyalgia
- • Patients with any widespread inflammatory musculoskeletal disorders, widespread rheumatic diseases other than fibromyalgia, active infections, or untreated endocrine disorders
- • CLcr less than 60 mL/min (estimated from serum creatinine)
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Shanghai, , China
Guangzhou, Guangdong, China
Bengbu, Anhui, China
Hefei, Anhui, China
Beijing, Beijing, China
Chongqing, Chongqing, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Harbin, Heilongjiang, China
Harbin, Heilongjiang, China
Changsha, Kaifu District, Hunan, China
Nanchang, Jiangxi, China
Shanghai, Shanghai, China
Xi'an, Shanxi, China
Chengdu, Sichuan, China
Kunming, Yunnan, China
Wenzhou, Zhejiang, China
Beijing, , China
Beijing, , China
Beijing, , China
Shanghai, , China
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials